Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Health technology company Royal Philips has unveiled its sustainability impact plan, including decreasing the number of staff and reenforcing supply chain reliability.


Helping patients and consumers live healthier lives

Philips believes that there’s always a way to make life better and has been working for 130 years to help people live healthier lives - from focusing on fighting the spread of disease to ergonomic shaving products to clear lighting. 

Founded in 1891 in Eindhoven, the Netherlands, by father and son Frederik and Gerard Philips, the company helped introduce electricity to consumers and then many electrical products. Post-war, Philips Research developed healthcare technology using UV light, magnetic materials and more. 

In the last ten years, the company has truly become a focused leader in health technology.

Now, it looks forward to a sustainable future - but it’s one that comes at a cost.

The global Philips workforce will be reduced by 6,000 roles by 2025, to increase savings and competitiveness.

Philips is also redesigning its products to remove risks from supplies and delivery. It is hoped that this will build more predictable financial results.

The company plans to focus on progressive value creation by uplifting the impact of patient-centric innovation. The key value priorities will be: 

1) Patient safety and quality

2) Supply chain reliability

3) A simplified, more agile operating model. This will be supported by a reinvigorated culture of accountability, and strong health technology talent and capabilities.

Royal Philips to enhance supply chain reliability

Roy Jakobs, CEO of Royal Philips, said that while he was proud of the 130 year old company, he felt that there was room for improvement within, to safeguard the future. 

“Philips has built leading market positions based on meaningful innovations and high customer intimacy, further supported by a compelling purpose, a strong brand, and clear ESG commitments. However, given our significant operational challenges, we are not fully extracting the full value of our businesses, as also reflected in our 2022 results.

“During my first 100 days, I have worked with our team on the urgent interventions needed to improve our execution and performance. This includes bolstering our culture with enhanced accountability and strengthening our health technology talent and capabilities.

“Our strategy will focus on organic growth through patient and people-centric innovation at scale, with a strong improvement in execution as key value driver. This will be enabled by strengthening our patient safety and quality management and completing the Respironics recall. We will also urgently enhance the supply chain reliability to improve performance and simplify our way of working to improve our agility and productivity. This includes the difficult, but necessary further reduction of our workforce by around 6,000 roles globally by 2025.”

Jakobs is confident that this plan will put Philips on a continuous path to sustainable value creation.


Featured Articles

Hospitals must embrace IoMT device security

As cybersecurity threats rise in the healthcare sector, hospitals must get serious about IoMT device protection, says Shankar Somasundaram, CEO of Asimily

Mental health support for working women and mothers

Dr. Kylie Bennett, Mental Health Program Director at Dialogue, is committed to supporting women in the workplace - especially Mothers - and their health

Digital evolution delivers better healthcare outcomes

Hannah Graham, Group Account Director at digital transformation consultancy Equator, shares how digitisation is building positive changes in healthcare

Hyfe AI uses acoustic AI in its digital cough monitoring

Technology & AI

Siemens: smart finance to help medical technology growth

Technology & AI

Healthcare Digital news roundup: prostate cancer & AI

Medical Devices & Pharma